METHOD FOR COMBINATION THERAPY OF RETINOVASCULAR MACULAR OEDEMA Russian patent published in 2014 - IPC A61F9/08 A61K39/395 A61P27/02 

FIELD: medicine.

SUBSTANCE: vasoendothelial growth factor inhibitor is introduced intravitreally (pars plana). That is followed by one-stage subthreshold micropulse laser coagulation 30 minutes later of the entire macular region, except for a central avascular zone in staggered circular lines. Distances of the laser coagulates in the entire area of exposure are equal to one coagulate. A laser processing of a perimacular area is further performed with a double distance of the laser coagulates and at lesser radiation power up to 800 mW short of 500 mcm to temporal vascular arcade in diabetic retinopathy, or upper or lower half of the perimacular area in thrombosis of a central retinal vein branch. The method provides higher early clinical effectiveness in the macular oedema until observing irreversible changes and stable visual deterioration, recovering the visual functions of the central retina by the atraumatic effect of the above laser parameters, treating the entire ischemic area and vascular retinal leakage.

EFFECT: administering vasoendothelial growth factor inhibitor provides recovery of the disturbed cytoarchitectonics of the evascular wall, reducing its permeability and transudation, desolating all the new vessels, reducing secondary oedemas of the optic disk.

2 dwg, 1 ex